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S UMM A R Y
S E T T I NG : Intradermal injection using a syringe and
needle is generally accepted as the most accurate method
for the tuberculin skin test (TST). However, the
Mantoux technique using a conventional needle is often
difficult to perform reliably, affecting testing results and
safety.
OB J E C T I V E : We evaluated the efficacy and safety of a
novel intradermal injection device, the MicronJet600TM
microneedle, compared with conventional injection in
terms of skin reactivity to the TST.
DE S I GN : A prospective, open-label clinical study was
conducted. The TST was administered by both methods
in the same subject. For pain assessment, participants
filled in a visual analogue scale (VAS) after each TST.
Any side effects due to TST or injections were observed.
R E SU LT S : TST reaction rates (cut-off 75 mm) from
microneedles and needles were respectively 44.0% and
47.2%, with no significant difference between the two.
Furthermore, agreement of positivity between the two
methods was excellent with both 5 mm and 10 mm cut-
off values. However, the level of pain experienced when
microneedles were used for TST was significantly lower
than with conventional needles. No adverse effects were
attributed to the MicronJet device.
CONC LU S I ON : The novel microneedle device used for
TST in this study was effective, safe and less painful in
healthy adult volunteers.
K E Y WO RD S : microneedle device; TST; Mantoux;
intradermal
TUBERCULOSIS (TB) REMAINS a major public
health problem in the world. It is known that one
third of the world’s population has latent tuberculous
infection (LTBI); these individuals have been infected
with Mycobacterium tuberculosis, but have not yet
clinically developed the disease.1 Accurate diagnosis
of LTBI, followed by proper chemoprophylaxis,
might be an effective way to control TB and prevent
it from spreading within a high-risk population.
The tuberculin skin test (TST) is widely used for the
diagnosis of LTBI. Intradermal injection using a
syringe and needle, called the Mantoux technique,
is generally accepted as the most appropriate method
for the TST, as the delivered purified protein
derivative (PPD) dose (0.1 ml) can be precisely
measured and controlled, resulting in more consistent
mycobacteria-specific immunity.2–5 However, it re-
quires a well-trained nurse who is skilful with the
technique in the field to form a wheal with an
acceptable size of .6 mm in diameter, indicating
proper intradermal injection of PPD into the epider-
mal layers of the skin.6 The percutaneous method,
using a multipuncture device, has also been intro-
duced to overcome issues such as mass, and to
facilitate the rapid and less skillful administration of
the TST.7
A novel microneedle device for intradermal injec-
tion has recently been introduced to complement an
unmet need in the intradermal delivery of vaccines
and other biologics.8 The MicronJet600TM (Nano-
Pass Technologies Ltd, Nes Ziona, Israel) used in this
study is composed of three microneedles, 0.6 mm in
length, enabling controlled delivery depths with
minimal pain and lowered risk associated with
handling needles during injection. The device is
designed to be mounted on any standard syringe
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and used as a substitute for a conventional needle in
intradermal injection.9 Previous studies have shown
that various types of vaccines, such as the seasonal
and pandemic influenza vaccines, can be delivered via
the intradermal route with favourable efficacy and
safety, compared with intramuscular injection.8,10–14
In addition, MicronJet can be used for other drugs or
vaccines currently delivered by intradermal injection,
such as insulin, rabies, influenza and anthrax, to
control injection depth, reduce injection pain and
ease the need for skilled users.15
We conducted a study to evaluate the performance
of a novel microneedle device in the intradermal
injection of PPD in healthy volunteers. The aim of the
study was to compare the results of TSTadministered
using a conventional syringe and needle method and
the MicronJet method, in terms of efficacy and safety.
STUDY POPULATION AND METHODS
Study design and participants
This was a randomised, open-label study to evaluate
the efficacy and safety of the novel MicronJet
microneedle device for applying the TST in healthy
adults. Healthy volunteers aged 20–60 years were
recruited at a tertiary hospital, the Severance Hospi-
tal, Seoul, Republic of Korea, from November 2014
to March 2015. All participants were screened using
chest X-ray (CXR), and clinical information, includ-
ing history of BCG vaccination, TB, TST and other
comorbidities, was collected onto clinical research
forms on interview. Individuals with an abnormal
CXR or any chronic illness with immune suppression,
such as uncontrolled diabetic condition, chronic liver
disease, taking immunosuppressive agents, or history
of TB or TST, were excluded. After enrolment, a
trained nurse administered the TST twice for each
subject on both the left and the right arms, starting
with either the conventional needle or the micronee-
dle. The site of PPD injection using the microneedle
device was assigned by block randomisation.
Approval for the clinical study using an investiga-
tional medical device was provided by the Korean
Ministry of Food and Drug Safety, Seoul (Study No.
644). Ethical approval was provided by the Institu-
tional Research Board of Severance Hospital, Seoul,
Republic of Korea (IRB #1-2014-0026). All volun-
teers provided written informed consent to partici-
pate in the study.
Tuberculin skin test with a microneedle device and a
conventional needle
For each TST, 0.1 ml of 2 tuberculin units of
tuberculin PPD RT23 (Statens Serum Institut,
Copenhagen, Denmark) was administered on one
arm with a microneedle device and the other arm
with a conventional needle in the same subject by a
trained nurse. The MicronJet devices were donated
by NanoPass Technologies Ltd, and were used
according to the manufacturer’s instructions. To
assess the proper intradermal injection with 0.1 ml
of PPD, the size of the white vesicle (wheal) of each
injection site was measured in mm. For pain
assessment, a Visual Analogue Scale (VAS) pain
score graded 0 from 10 was recorded after each PPD
injection. After 48–72 h, the induration diameter
transverse to the long axis of the arm was measured
by two trained nurses. Any side effects due to TSTor
injections were observed before the skin reactions
were read.
Determination of the number of participants
The sample size of the study was determined by the
following factors: the previously reported rate of TST
reaction (75 mm) in Korean adults,16,17 significance
level and power, and equivalence margin difference in
rates of TST reaction between the two methods
(conventional needle and microneedle). Using an
equivalence test for two correlated rates and assum-
ing a value of 40% for the TST reaction (75 mm)
with a significance level of 0.05, a power of 0.80 and
an equivalence difference of 10%, the minimum
sample size was estimated to be 152.15
Statistical analysis
Data analyses were performed using SAS 9.3 software
(Statistical Analysis System, Cary, NC, USA). To
compare the TST indurations, VAS scores and wheal
sizes from the two methods of PPD administration in
each study subject, the paired t-test was used.
Comparison of the rates of TST reaction between
the two methods was performed using the McNemar
test. Relationships between the two methods were
analysed using j statistics and Pearson correlation
coefficient. In the j statistics, j . 0.75 represented
excellent agreement beyond chance, while j 0.4–0.75
represented fair to good agreement beyond chance.
Comparison of the primary outcome, i.e., rates of
TST reaction, between the two PPD administration
methods were evaluated with the lower boundary and
upper boundary of one-sided 95% confidence inter-
vals (CIs) using an SAS macro suggested by Tango




A total of 159 participants were enrolled in the study.
There were no losses to follow-up or dropouts during
the study. Of 159 participants, 63 (39.6%) were male
and 96 (60.4%) female; the mean age was 34.5 years
(range 20–59). From the BCG scar inspection at the
site, 145 (84.3%) participants still had BCG scars on
the left upper arm. The mean body mass index (BMI)
was 23.3 6 standard deviation (SD) 3.2 kg/m2; 8
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(5.0%) participants said that they had had contact
with TB patients in the past.
Efficacy
In terms of skin reactivity, we evaluated the efficacy
of TST using MicronJet devices compared with
conventional needles in 159 participants (Figure).
TST reaction positivity (cut-off 75 mm) from the
two methods of administration was 44.0% with
MicronJet and 47.2%with the needle. Similarly, the
TST positivity rates (cut-off710 mm) were 22.6%
with MicronJet and 22.0% with the needle. The
TST reaction with MicronJet was equivalent to that
seen with the conventional needle, as the lower and
upper boundary of differences measured were
within the pre-defined equivalence margin of 10%
(Table 1).
The mean induration sizes of the TST reaction,
after excluding non-reactors (induration 0 mm in
both groups), were 7.26 5.4 mmwithMicronJet and
7.5 6 4.9 mm with the needle; there was no
significant difference between the two methods (n ¼
110, P ¼ 0.062). However, the difference in mean
indurations of MicronJet and the needle approached
significance, mainly affected by two outliers with
respectively 0–5 mm and 0–8 mm in paired indura-
tion sizes of the MicronJet and the needle method.
When plotting the results of the TSTwith Micron-
Jet and the needle, paired TST indurations performed
by two methods of administration in the same subject
were well correlated (correlation coefficient¼ 0.970,
P¼0.0001). Agreement of TST positivity between the
MicronJet and the needle methods was excellent at
both 5 mm and 10 mm cut-offs (respectively j ¼
0.911 and j¼ 0.909) (Table 2). Using a 10 mm cut-
off, two participants showed 13 and 12 mm
indurations with the needle but 9.5 and 7.5 mm with
MicronJet, while three participants showed 10, 10
and 12 mm with MicronJet, but 9, 8.5 and 9.5 mm
with the needle, respectively.
Safety
During TSTadministration in 159 healthy volunteers,
one mild adverse skin reaction with redness, itchiness
and a blister that burst at the injection site was
observed due to TST reactivity itself. However, no
adverse events or safety concerns were attributed to
the microneedle device or conventional needle. No
breakage of microneedles was reported during the
study. There were no reports of any other mechanical
failures.
Usability
We evaluated the utility of the novel microneedle for
PPD injection for both participants and study nurses.
For study participants, we measured the relative
degree of pain following injections with both
microneedles and conventional needles. Among the
159 participants, the mean VAS pain score was 3.4 6
1.7 with MicronJet and 4.9 6 1.9 with the needle,
showing that pain scores with MicronJet were
significantly lower than with the other method (P ,
0.001) (Table 3).
In addition, we measured the size of the wheals
formed after each injection of 0.1 ml PPD; the wheals
should be.6 mm in diameter when successful. In this
study, all injections achieved the proper wheal size
(100%) according to current national guidelines.
However, microneedles yielded larger wheals than
did conventional needles (P , 0.0001; mean 8.52 vs.
7.67 mm).
DISCUSSION
In this study, we found that there were no significant
differences in TST reaction rates at 5 mm and 10 mm
cut-off between microneedles and conventional nee-
Figure Distribution of TST indurations with MicronJet600E
and the conventional injection needle (n¼159). TST¼ tuberculin
skin test.







5 mm 44.0 47.2 3.2 (6.6 to 0.5)
10 mm 22.6 22.0 0.6 (2.1 to 3.5)
*One-tailed.
TST¼ tuberculin skin test; CI¼ confidence interval.
Table 2 Agreement of TST-positive reaction rates between






Cut-off ,5 mm 75 mm Total
,5 mm 83 6 89 0.911
75 mm 1 69 70
Total 84 75 159
Cut-off ,10 mm 710 mm Total
,10 mm 121 2 123 0.909
710 mm 3 33 36
Total 124 35 159
TST¼ tuberculin skin test.
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dles. The difference in induration associated with the
use of the two methods was not statistically
significant, and correlations between the TST indu-
rations performed by the two methods in the same
subject were excellent. In addition, no adverse events
or safety concerns were attributed to microneedle
devices, with low pain response in participants and
acceptable usability in study nurses.
The TST and the interferon-gamma release assay
(IGRA) are currently used to diagnose LTBI world-
wide. Improvement of PPD delivery by the Mantoux
technique is important to TB control programmes for
LTBI screening in contact investigations, among
hospital employees and in national surveys. Where
nurses do not have training in TST application,
leakage of PPD solution at the injection site might
occur, necessitating repeated skin tests.20 Based on
our results, the 0.6 mm microneedle device allows
intradermal administration with minimal expertise
for the nurses who apply the TST injections and
minimal pain for the recipients, and shows valuable
advantages over conventional needles, including
reduced need for training and less needle fear, stress
and discomfort associated with intradermal injec-
tions. In addition, the use of a microneedle device
helps reduce any risks or injuries associated with the
handling of used needles at the field site, particularly
in a school setting.
To compare TST results between the two methods
in our study, two trained nurses independently
measured the indurations of the skin reaction, and
were blinded to the injection method on each arm.
Although there were two or three notable differences
in readings, most were well correlated between two
nurses (Spearman rank correlation ¼ 0.96 with
MicronJet, 0.95 with the needle); we thus averaged
readings from the two nurses for each of the methods.
One of the key factors for the interpretation of TST
reading variability can be intra- and inter-observer
consistency between different readers, which should
be controlled and minimised by training.21–23 With
respect to the unavoidable reading variations in the
TST, the small differences in TST results between the
MicronJet and the needle methods in our study could
be acceptable in the field.
Regarding pain assessment in this study, partici-
pants marked lower pain scores for TST using
microneedles compared to conventional needles,
but the difference in score (1.4) was not as large as
expected, although it was significant. This might be
because our study participants were adults aged 20–
60 years (mean age 34.5); this age group tends to
have less needle fear than children or young
adults.24 The difference in pain scores might have
been greater if we had performed the TST in
children or young adults. Taking into consideration
the greater needle fear in children and young adults,
we expect that the microneedle device, MicronJet
may be feasible for contact investigation that occurs
mainly in schools.
By introducing microneedle-based delivery of PPD,
specific hurdles of the TST related to injection skills,
safety, and pain due to conventional needles may be
overcome. However, the limitations of the TST itself,
due to possible errors made by examiners, previous
BCG vaccination or infection with non-tuberculous
mycobacteria, remain unresolved. Although the
agreement of TST reactivity between microneedles
and needles was excellent in our study, we noted
several participants with different sizes of induration
near the 10-mm cut-off, which might affect the
determination of LTBI diagnosis in the field. This
suggests that without improved skills for the mea-
surement of induration (‘by definition’) and the
interpretation of tests in different populations,
despite administration using microneedles, the TST
still has limitations in the diagnosis of LTBI.
The usefulness of this microneedle-based device is
not restricted to the TST. It may be extended to BCG
vaccination (or novel TB vaccination with intradermal
delivery) and any drug deliveries requiring intrader-
mal injection, as shown in recent studies.10–14 Unlike
percutaneous administration by other multipuncture
devices for the BCG vaccination, if validated by a
clinical study, MicronJet may deliver the BCG vaccine
(or novel TB vaccines) by intradermal administration,
by which the delivered dose can be precisely measured
and administration can be controlled, resulting in
improved mycobacteria-specific immunity.2,25,26
CONCLUSION
In this study, we found that the use of microneedle
devices did not negatively affect the result of the TST,
and that an acceptable amount of PPD was admin-
istered to the Mantoux recipient with less pain
compared with that of conventional needles. In
addition, no adverse events or safety concerns were
Table 3 Comparison of VAS pain scores
VAS pain MicronJet600E Needle Difference* t-statistics P value*
Mean 6 SD 3.4 6 1.7 4.9 6 1.9 1.4 6 1.8 9.86 ,0.001
Median (min-max) 3 (0–9) 5 (1–10) — — —
*The difference in scores was calculated by subtracting the VAS pain score for the MicronJet method from that for the
needle method for each subject.
VAS¼ Visual Analogue Scale; SD¼ standard deviation.
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attributed to the microneedle device. Overall, among
159 healthy participants, the TST using microneedles
was as effective and safe as a conventional needle.
The use of a novel microneedle device can therefore
be expanded to the TST.
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R E S U M E
CONT EX T E : Une injection intradermique a` l’aide d’une
seringue et d’une aiguille est ge´ne´ralement accepte´e
comme la me´thode la plus pre´cise pour effectuer le test
cutane´ a` la tuberculine (TST). Cependant, la technique
de Mantoux, qui recourt a` une aiguille conventionnelle,
est souvent difficile a` re´aliser de manie`re fiable, ce qui
affecte a` la fois les re´sultats du test et sa se´curite´.
OB J E C T I F : Nous avons e´value´ l’efficacite´ et la se´curite´
d’une nouvelle technique d’injection intradermique a`
l’aide d’une microaiguille (MicronJet600TM) compare´e
a` l’injection conventionnelle, en termes de re´activite´
cutane´e au TST.
S CH E´MA : Une e´tude clinique ouverte prospective a e´te´
re´alise´e. Les TST ont e´te´ faits selon les deux me´thodes
sur le meˆme sujet. Les participants ont rempli une e´chelle
analogue visuelle (VAS) apre`s chaque TST afin d’e´valuer
la douleur provoque´e. Tout effet secondaire duˆ au TST
ou aux injections a e´te´ observe´.
R E´ S U LTAT S : Les taux de re´action au TST (seuil 75
mm) dus aux microaiguilles et aux aiguilles ont e´te´
respectivement de 44,0% et 47,2%, sans diffe´rence
significative entre les deux. De plus, l’accord de
positivite´ entre les deux me´thodes a e´te´ excellent avec
des valeurs de seuil d’a` la fois 5 mm et 10 mm.
Cependant, le niveau de douleur ressenti avec
l’utilisation des microaiguilles a e´te´ significativement
plus faible qu’avec les aiguilles conventionnelles. Aucun
effet secondaire n’a e´te´ attribue´ au MicronJet.
CONC LU S I ON : La nouvelle microaiguille utilise´e pour
le TST dans cette e´tude s’est ave´re´e efficace, suˆre et
moins douloureuse chez des adultes sains volontaires.
R E S UM E N
MARCO DE R E F E R ENC I A: En general, se acepta que el
me´todo ma´s preciso de practicar la prueba tuberculı´nica
(TST) es una inyeccio´n intrade´rmica utilizando una
jeringuilla con aguja. Sin embargo, la te´cnica cla´sica de
Mantoux con una aguja corriente suele ser difı´cil de
llevar a cabo de manera fiable, lo cual altera los
resultados TST y modifica su seguridad.
OB J E C T I VO: Evaluar la eficacia y la inocuidad de un
nuevo tipo de inyeccio´n intrade´rmica, utilizando una
microaguja (MicronJet600e) y comparar con la
inyeccio´n cla´sica, con respecto a la reactividad cuta´nea
a la TST.
M E´ TODOS: Fue este un estudio clı´nico prospectivo sin
enmascaramiento. Se practico´ a cada persona la prueba
TST mediante dos me´todos. Los participantes
completaron una escala analo´gica visual (VAS) con el
fin de evaluar el dolor despue´s de cada prueba. No se
observaron reacciones adversas debidas a la tuberculina
ni a las inyecciones.
R E S U LTA D O S: La tasa de reaccio´n TST con la
microaguja fue 44,0% y con las agujas cla´sicas fue
47,2% (induracio´n discriminatoria 75 mm), una
diferencia sin significacio´n estadı´stica. Adema´s, la
concordancia de la positividad de la reaccio´n fue
excelente con ambos umbrales discriminatorios (5 mm
y 10 mm). Sin embargo, el grado VAS de dolor referido
fue significativamente inferior cuando se usaron
microagujas en comparacio´n con las agujas cla´sicas.
No se atribuyeron reacciones adversas a la utilizacio´n
del dispositivo MicronJet.
CONC LU S I O´ N: En el presente estudio, la utilizacio´n del
nuevo dispositivo con microaguja en la prueba TST fue
eficaz, segura y menos dolorosa en los adultos sanos
voluntarios que participaron.
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